Internet-delivered interventions for people with depression and anxiety in IAPT services

Conditions

Depression and anxiety disorders Mental and Behavioural Disorders Depression and anxiety disorders

Ángel Enrique, Nora Eilert, Rebecca Wogan, Caroline Earley, Daniel Duffy et al. (8 authors)

Cognitive Therapy and Research2021-01-1815 citations

A pragmatic randomized waitlist-controlled effectiveness and cost-effectiveness trial of digital interventions for depression and anxiety.

Richards D, Enrique A, Eilert N, Franklin M, Palacios J, Duffy D, Earley C, Chapman J, Jell G, Sollesse S, Timulak L.

2020-06-1583 citations

10.1038/s41746-020-0293-8

Digital IAPT: the effectiveness & cost-effectiveness of internet-delivered interventions for depression and anxiety disorders in the Improving Access to Psychological Therapies programme: study protocol for a randomised control trial.

Richards D, Duffy D, Blackburn B, Earley C, Enrique A, Palacios J, Franklin M, Clarke G, Sollesse S, Connell S, Timulak L.

2018-03-0238 citations

10.1186/s12888-018-1639-5

Interventions

Post diagnostic assessment participants will be randomised to either the immediate treatment (depression or anxiety) or a waiting list control group using random permuted blocks using block sizes of 9

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. A score of = 9 on PHQ-9 and/ or a score of = 8 on GAD-7 2. 18 years of age 3. Suitable for an internet-delivered intervention (iCBT) 4. Users of the Berkshire NHS Trust IAPT Talking Therapies Step 2 services

Exclusion criteria

Exclusion criteria: 1. Suicidal intent/ideation 2. Psychotic illness 3. Currently in psychological treatment for depression and/or anxiety 4. Alcohol or drug misuse 5. Previous diagnosis of an organic mental health disorder

Design outcomes

Primary

Measure	Time frame
1. Depression is assessed using the Patient Health Questionnaire-9 (PHQ-9) at baseline, throughout treatment, at 8 weeks and at 3, 6, 9 and 12 months follow-up 2. Anxiety is assessed using the Generalized Anxiety Disorder-7 (GAD-7) at baseline, throughout treatment, at 8 weeks and at 3, 6, 9 and 12 months follow-up	—

Secondary

Measure	Time frame
1. Diagnosis of depression or anxiety for research purposes will be established using the M.I.N.I. International Neuropsychiatric Interview 7.0 (MINI) at baseline and 3 months follow-up 2. Work and social adjustment is assessed using the Work and Social Adjustment (WASA)at baseline, throughout treatment, at 8 weeks and at 3, 6, 9 and 12 months follow-up 3. Social Anxiety is assessed using the Social Phobia Inventory (SPIN)at baseline, throughout treatment, at 8 weeks and at 3, 6, 9 and 12 months follow-up 4. Health Anxiety is assessed using the Short Health Anxiety Inventory (HAI) at baseline, throughout treatment, at 8 weeks and at 3, 6, 9 and 12 months follow-up 5. Panic is assessed using the Panic Disorder Severity Scale-Self Report (PDSS-SR)at baseline, throughout treatment, at 8 weeks and at 3, 6, 9 and 12 months follow-up 6. GAD symptoms are assessed using the Penn State Worry Questionnaire (PSWQ) at baseline, throughout treatment, at 8 weeks and at 3, 6, 9 and 12 months follow-up 7. Quality of life for users of mental health services is assessed using the Recovering Quality of Life scale (ReQoL)at baseline, throughout treatment, at 8 weeks and at 3, 6, 9 and 12 months follow-up 8. Client service usage is assessed using the Client Service Receipt Inventory (CSRI)at baseline, throughout treatment, at 8 weeks and at 6, 9 and 12 months follow-up 9. Emotion regulation is assessed using the Emotion Regulation Questionnaire (ERQ) at baseline and at 8 weeks 10. Rumination is assessed using the Positive Beliefs about Depressive Rumination Scale – adapted (PBRS-A) version at baseline and 8 weeks 11. Therapeutic Expectancy is assessed using the Expectancy and Credibility Questionnaire (ECQ) for the treatment group at baseline, 4 and 8 weeks 12. Therapeutic Alliance for patients is assessed using the Scale to Assess Therapeutic Relationships – Patient Version (STAR-P) throughout treatment 13. Therapeutic Alliance for clinicians is assessed using the Scale to Assess Thera	—

Measure

Time frame

1. Diagnosis of depression or anxiety for research purposes will be established using the M.I.N.I. International Neuropsychiatric Interview 7.0 (MINI) at baseline and 3 months follow-up 2. Work and social adjustment is assessed using the Work and Social Adjustment (WASA)at baseline, throughout treatment, at 8 weeks and at 3, 6, 9 and 12 months follow-up 3. Social Anxiety is assessed using the Social Phobia Inventory (SPIN)at baseline, throughout treatment, at 8 weeks and at 3, 6, 9 and 12 months follow-up 4. Health Anxiety is assessed using the Short Health Anxiety Inventory (HAI) at baseline, throughout treatment, at 8 weeks and at 3, 6, 9 and 12 months follow-up 5. Panic is assessed using the Panic Disorder Severity Scale-Self Report (PDSS-SR)at baseline, throughout treatment, at 8 weeks and at 3, 6, 9 and 12 months follow-up 6. GAD symptoms are assessed using the Penn State Worry Questionnaire (PSWQ) at baseline, throughout treatment, at 8 weeks and at 3, 6, 9 and 12 months follow-up 7. Quality of life for users of mental health services is assessed using the Recovering Quality of Life scale (ReQoL)at baseline, throughout treatment, at 8 weeks and at 3, 6, 9 and 12 months follow-up 8. Client service usage is assessed using the Client Service Receipt Inventory (CSRI)at baseline, throughout treatment, at 8 weeks and at 6, 9 and 12 months follow-up 9. Emotion regulation is assessed using the Emotion Regulation Questionnaire (ERQ) at baseline and at 8 weeks 10. Rumination is assessed using the Positive Beliefs about Depressive Rumination Scale – adapted (PBRS-A) version at baseline and 8 weeks 11. Therapeutic Expectancy is assessed using the Expectancy and Credibility Questionnaire (ECQ) for the treatment group at baseline, 4 and 8 weeks 12. Therapeutic Alliance for patients is assessed using the Scale to Assess Therapeutic Relationships – Patient Version (STAR-P) throughout treatment 13. Therapeutic Alliance for clinicians is assessed using the Scale to Assess Thera

—

Countries

England, United Kingdom

Outcome results

None listed